ArticleAmerican journal of hematology2021

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.

Naval Daver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.